These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease. Savelieff MG; DeToma AS; Derrick JS; Lim MH Acc Chem Res; 2014 Aug; 47(8):2475-82. PubMed ID: 25080056 [TBL] [Abstract][Full Text] [Related]
8. Unraveling the early events of amyloid-β protein (Aβ) aggregation: techniques for the determination of Aβ aggregate size. Pryor NE; Moss MA; Hestekin CN Int J Mol Sci; 2012; 13(3):3038-3072. PubMed ID: 22489141 [TBL] [Abstract][Full Text] [Related]
9. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters. Matsuzaki K Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558 [TBL] [Abstract][Full Text] [Related]
11. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Thal DR; Walter J; Saido TC; Fändrich M Acta Neuropathol; 2015 Feb; 129(2):167-82. PubMed ID: 25534025 [TBL] [Abstract][Full Text] [Related]
13. Jean L; Brimijoin S; Vaux DJ J Biol Chem; 2019 Apr; 294(16):6253-6272. PubMed ID: 30787102 [TBL] [Abstract][Full Text] [Related]
14. Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Rudinskiy N; Fuerer C; Demurtas D; Zamorano S; De Piano C; Herrmann AG; Spires-Jones TL; Oeckl P; Otto M; Frosch MP; Moniatte M; Hyman BT; Schmid AW Alzheimers Dement; 2016 Sep; 12(9):996-1013. PubMed ID: 27130892 [TBL] [Abstract][Full Text] [Related]
15. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease. Behl T; Kaur I; Fratila O; Brata R; Bungau S Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199 [TBL] [Abstract][Full Text] [Related]
16. The inhibition of cellular toxicity of amyloid-β by dissociated transthyretin. Cao Q; Anderson DH; Liang WY; Chou J; Saelices L J Biol Chem; 2020 Oct; 295(41):14015-14024. PubMed ID: 32769117 [TBL] [Abstract][Full Text] [Related]
17. High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer. Robb E; Perez K; Hung LW; Masters CL; Barnham KJ; Cherny RA; Bush AI; Adlard PA; Finkelstein DI J Alzheimers Dis; 2015; 44(1):69-78. PubMed ID: 25182735 [TBL] [Abstract][Full Text] [Related]
18. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease? Dunys J; Valverde A; Checler F J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530 [TBL] [Abstract][Full Text] [Related]
19. Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. Guzmán EA; Bouter Y; Richard BC; Lannfelt L; Ingelsson M; Paetau A; Verkkoniemi-Ahola A; Wirths O; Bayer TA Mol Neurodegener; 2014 Apr; 9():13. PubMed ID: 24694184 [TBL] [Abstract][Full Text] [Related]
20. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease. Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]